Financial Position and Cash Runway - Cash, cash equivalents, and investments totaled $334.4 million as of June 30, 2024, providing a cash runway into 2027[7][15] - Total assets increased to $344.79 million as of June 30, 2024, compared to $210.30 million as of December 31, 2023[15] Operating Expenses and Net Loss - Research and development expenses increased to $15.7 million in Q2 2024, up from $14.5 million in Q2 2023, driven by employee compensation and clinical trial costs[8] - General and administrative expenses rose to $6.2 million in Q2 2024, compared to $1.9 million in Q2 2023, due to increased headcount and consulting expenses[9] - Net loss for Q2 2024 was $17.5 million, compared to $16.1 million in Q2 2023, with basic and diluted net loss per share of $0.68 and $16.29, respectively[10] - Total operating expenses for Q2 2024 were $21.97 million, up from $16.37 million in Q2 2023[14] Clinical Trials and Development Progress - The first patient was dosed in May 2024 in the Phase 2 TRANQUILITY trial evaluating pacibekitug for cardiovascular diseases[1][4] - Tourmaline is on track to initiate a pivotal Phase 3 trial for pacibekitug in Thyroid Eye Disease (TED) in the second half of 2024, with topline data expected in 2026[3] - Topline data from the Phase 2 TRANQUILITY trial is expected in the first half of 2025, potentially positioning the company for Phase 3 readiness in cardiovascular diseases[4][5] Corporate and Market Recognition - Tourmaline was added to the Russell 2000® and Russell 3000® Indexes in June 2024[6]

– First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000® Index and the broad-market Russell 3000® Index in June 2024 – – Cash, cash equivalents and investments of $334.4 million as of June 30, 2024, providing ...

Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling — Topline data is expected first half of 2025 — D ...

NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in addition to servin ...

Mr. Robinson earned a B.S. in Management and an M.S. in Accounting from Boston College, and he is licensed as a Certified Public Accountant. NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, eff ...

A live webcast and replay will be posted under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at https://ir.tourmalinebio.com. NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40384 __________________________________________________________ TOURMALINE BIO ...

Exhibit 99.1 Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights – Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K _____________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-40384 ________________________________________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40384 TOURMALINE BIO, INC. (Exact Name of Registrant as Specified in its Charter) (State or Other Jurisdiction of Incorporat ...